{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:43:43Z","timestamp":1793785423588,"version":"4.6.1"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"Importance<\/jats:title>Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy. A standard therapy is still lacking.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the activity and safety of camrelizumab (an anti\u2013programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this single-arm, single-center, phase 2 nonrandomized clinical trial, patients with treatment-naive unresectable stage III or IV acral melanoma were enrolled at Peking University Cancer Hospital and Institute between June 4, 2020, and August 24, 2021. The data cutoff date was April 10, 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients received 4-week cycles of intravenous camrelizumab, 200 mg, every 2 weeks; oral apatinib 250 mg, once daily; and intravenous temozolomide, 200 mg\/m2<\/jats:sup>, once daily on days 1 to 5 until disease progression or unacceptable toxic effects.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was objective response rate as assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (version 1.1). Secondary end points included progression-free survival, time to response, duration of response, disease control rate, overall survival, and safety.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 50 patients (32 men [64%]; median age, 57 years [IQR, 52-62 years]) were enrolled and received treatment. The median follow-up duration was 13.4 months (IQR, 9.6-16.2 months). The objective response rate was 64.0% (32 of 50; 95% CI, 49.2%-77.1%). The median time to response and duration of response were 2.7 months (IQR, 0.9-2.9 months) and 17.5 months (95% CI, 12.0 to not reached), respectively. The disease control rate was 88.0% (44 of 50; 95% CI, 75.7%-95.5%). The estimated median progression-free survival was 18.4 months (95% CI, 10.6 to not reached). The median overall survival was not reached. The most common grade 3 or 4 treatment-related adverse events were increased gamma-glutamyltransferase levels (15 [30%]), decreased neutrophil count (11 [22%]), increased conjugated bilirubin levels (10 [20%]), and increased aspartate aminotransferase levels (10 [20%]). No treatment-related deaths occurred.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this nonrandomized clinical trial suggest that camrelizumab plus apatinib and temozolomide may be a potential first-line treatment option for patients with advanced acral melanoma, which warrants further validation in a randomized clinical trial.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04397770<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.1363","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T15:32:32Z","timestamp":1685633552000},"page":"1099","source":"Crossref","is-referenced-by-count":37,"title":["Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma"],"prefix":"10.1001","volume":"9","author":[{"given":"Lili","family":"Mao","sequence":"first","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caili","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengzhuo","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangzhou","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"coi230019r1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"issue":"5","key":"coi230019r2","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/cam4.2019.8.issue-5","article-title":"Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma.","volume":"8","author":"Fujisawa","year":"2019","journal-title":"Cancer Med"},{"issue":"20","key":"coi230019r3","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma.","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"issue":"7653","key":"coi230019r4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes.","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"issue":"12","key":"coi230019r5","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1158\/2159-8290.CD-22-0603","article-title":"Comparative genomics provides etiologic and biological insight into melanoma subtypes.","volume":"12","author":"Newell","year":"2022","journal-title":"Cancer Discov"},{"issue":"9","key":"coi230019r7","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","article-title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.","volume":"31","author":"Nakamura","year":"2020","journal-title":"Ann Oncol"},{"key":"coi230019r8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2022.02.026","article-title":"Response to immune checkpoint inhibitors in acral melanoma: a nationwide cohort study.","volume":"167","author":"van Not","year":"2022","journal-title":"Eur J Cancer"},{"issue":"7","key":"coi230019r9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004668","article-title":"Efficacy of anti\u2013PD-1 and ipilimumab alone or in combination in acral melanoma.","volume":"10","author":"Bhave","year":"2022","journal-title":"J Immunother Cancer"},{"key":"coi230019r10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2022.08.030","article-title":"Efficacy comparison between anti\u2013PD-1 antibody monotherapy and anti\u2013PD-1 plus anti\u2013CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: a retrospective, multicenter study of 254 Japanese patients.","volume":"176","author":"Nakamura","year":"2022","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi230019r11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"coi230019r12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2020.12.021","article-title":"Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: an analysis of 112 cases.","volume":"145","author":"Fujisawa","year":"2021","journal-title":"Eur J Cancer"},{"key":"coi230019r13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720044","article-title":"Overall survival of patients with unresectable or metastatic BRAF V600\u2013mutant acral\/cutaneous melanoma administered dabrafenib plus trametinib: long-term follow-up of a multicenter, single-arm phase IIa trial.","volume":"11","author":"Mao","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"coi230019r14","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/jnci\/djz005","article-title":"Targeted genomic profiling of acral melanoma.","volume":"111","author":"Yeh","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"coi230019r15","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1158\/1078-0432.CCR-21-3344","article-title":"Integrative genomic profiling uncovers therapeutic targets of acral melanoma in Asian populations.","volume":"28","author":"Shi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"coi230019r16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ejca.2021.08.015","article-title":"c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.","volume":"157","author":"Steeb","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"coi230019r17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"issue":"1","key":"coi230019r18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"issue":"12","key":"coi230019r19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"coi230019r20","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma.","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"coi230019r21","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"coi230019r22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer.","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"32","key":"coi230019r23","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death\u20131, in patients with metastatic mucosal melanoma: an open-label phase IB trial.","volume":"37","author":"Sheng","year":"2019","journal-title":"J Clin Oncol"},{"issue":"21","key":"coi230019r24","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-22-1528","article-title":"Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II study.","volume":"28","author":"Mao","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"coi230019r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200845","article-title":"In vitro and in vivo apatinib inhibits vasculogenic mimicry in melanoma MUM-2B cells.","volume":"13","author":"Liu","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"coi230019r26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.bbrc.2019.10.084","article-title":"Apatinib-loaded nanoparticles inhibit tumor growth and angiogenesis in a model of melanoma.","volume":"521","author":"Zhang","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"coi230019r27","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1093\/oncolo\/oyab068","article-title":"Efficacy and safety of apatinib in patients with recurrent or refractory melanoma.","volume":"27","author":"Yuan","year":"2022","journal-title":"Oncologist"},{"key":"coi230019r28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2022.12.027","article-title":"Apatinib combined with camrelizumab in advanced acral melanoma patients: an open-label, single-arm phase 2 trial.","volume":"182","author":"Wang","year":"2023","journal-title":"Eur J Cancer"},{"issue":"24","key":"coi230019r29","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"coi230019r30","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","article-title":"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi230019r31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/cac2.v40.12","article-title":"Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.","volume":"40","author":"Zhang","year":"2020","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"coi230019r32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"issue":"35","key":"coi230019r33","doi-asserted-by":"publisher","first-page":"9001","DOI":"10.1200\/JCO.2005.01.1551","article-title":"Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.","volume":"23","author":"Kaufmann","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi230019r34","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23288","article-title":"Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients.","volume":"2","author":"Iversen","year":"2013","journal-title":"Oncoimmunology"},{"issue":"2","key":"coi230019r35","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.978709","article-title":"Tumor stroma and chemokines control T-cell migration into melanoma following temozolomide treatment.","volume":"4","author":"Tan","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"coi230019r36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"coi230019r37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1186\/s12885-022-09663-5","article-title":"Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study.","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"coi230019r38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti\u2013PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study.","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"coi230019r39","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-20-3136","article-title":"Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy.","volume":"27","author":"Zhou","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"coi230019r40","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151).","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"issue":"9","key":"coi230019r41","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"33","key":"coi230019r42","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1200\/JCO.20.00995","article-title":"Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma.","volume":"38","author":"Robert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi230019r43","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"coi230019r44","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade.","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"issue":"7","key":"coi230019r45","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","article-title":"Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients.","volume":"12","author":"Crisafulli","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"coi230019r46","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100949","article-title":"Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy.","volume":"14","author":"Wang","year":"2021","journal-title":"Transl Oncol"},{"issue":"4","key":"coi230019r47","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial.","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi230019r48","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.","volume":"7","author":"Meng","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"coi230019r49","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/annonc\/mdi190","article-title":"Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.","volume":"16","author":"Bafaloukos","year":"2005","journal-title":"Ann Oncol"},{"key":"coi230019r6","unstructured":"National Comprehensive Cancer Network. Melanoma: cutaneous, version 3. Accessed April 11, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2805681\/jamaoncology_mao_2023_oi_230019_1691789048.04215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T15:25:23Z","timestamp":1692285923000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2805681"}},"subtitle":["The CAP 03 Phase 2 Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.1363","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}